Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Inc. (AGEN) announced positive results from the Phase 2 UNICORN trial of its cancer treatments, botensilimab (BOT) and balstilimab (BAL), in colon cancer. The trial met its primary endpoint, with a 36% major pathologic response rate in pMMR/MSS colon cancer patients treated with BOT+BAL. No patients in the combination cohorts experienced cancer recurrence, with 12-month event-free survival at 100%. The findings support Agenus' planned Phase 3 ROBBIN trial in MSS/pMMR colon cancer.
How this was made
The 30-second read
Why it matters
The trial demonstrates that adding BAL to BOT yields major and complete pathologic responses, a first for MSS colon cancer, potentially opening a large market.
Market read
First public disclosure of significant Phase 2 data for a novel immunotherapy combo in a prevalent cancer subtype, likely to move Agenus and related biotech stocks.
What to watch
Small patient numbers and non‑randomized design could limit confidence; regulatory timelines remain uncertain.
Background
Agenus (NASDAQ: AGEN) focuses on multifunctional checkpoint antibodies. The UNICORN trial is investigator‑sponsored and follows the earlier NEST study.
Ticker impact
Agenus announced peer‑reviewed Phase 2 UNICORN trial results showing deep pathologic responses in MSS colon cancer.
upward pressure as market prices in strong efficacy signals.
First disclosure of robust Phase 2 results for a novel anti‑CTLA‑4/PD‑1 combo in a large patient subset.
Market effects
Strengthens the immuno‑oncology pipeline and may boost peer biotech stocks developing combination checkpoint therapies.
US biotech sector may see modest gains; European and Asian peers could see similar sentiment.
Highlights the potential of neoadjuvant immunotherapy for common MSS colorectal cancers worldwide.
Counterpoint
If the data cannot be replicated in a larger Phase 3, the hype may reverse, leading to a sell‑off.
Key entities
- companyAgenus Inc.
Developer of botensilimab (BOT) and balstilimab (BAL).
- clinical_trialROBBIN trial
Planned global Phase 3 study to confirm neoadjuvant BOT+BAL efficacy.
